Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements study uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://johnf075ddn5.blog-mall.com/profile